Fast clearing RGD-based near-infrared fluorescent probes for in vivo tumor diagnosis

Contrast Media and Molecular Imaging

Volumn 7, Issue 4, 2012, Pages 390-402

  Cao, Jie ^a   Wan, Shunan ^a   Tian, Junmei ^a   Li, Siwen ^a   Deng, Dawei ^a   Qian, Zhiyu ^b   Gu, Yueqing ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY OF AERONAUTICS AND ASTRONAUTICS   (China)

Author keywords

In vivo diagnosis; Integrin 3; Near infrared; RGD

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CONTRAST MEDIUM; ICG DER 02; INTEGRIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER DIAGNOSIS; CONFOCAL MICROSCOPY; CONJUGATION; CONTROLLED STUDY; COVALENT BOND; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEAR INFRARED SPECTROSCOPY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR SENSITIVITY;

ANIMALS; BIOLOGICAL ASSAY; CELL LINE, TUMOR; FLUORESCENT DYES; HUMANS; INJECTIONS, INTRAVENOUS; INTEGRIN ALPHAVBETA3; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NEOPLASMS; OLIGOPEPTIDES; ORGAN SPECIFICITY; PROTEIN BINDING; SPECTROMETRY, FLUORESCENCE; SPECTROSCOPY, NEAR-INFRARED; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861682414     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.1464     Document Type: Article

References (36)

1. Huveneers S, Truong H, Danen HJ. Integrins: signaling, disease, and therapy. Int J Radiat Biol 2007; 83(11-12): 743-751.
2. Lee S, Xie J, Chen XY. Peptide-based probes for targeted molecular imaging. Biochemistry 2010; 49: 1364-1376.
3. 3 expression with cy7-labeled RGD multimers. Mol Imaging Biol 2006; 8: 226-236.
4. Fass L. Imaging and cancer: a review. Mol Oncol 2008; 2(2): 115-152.
5. Cai W, Niu G, Chen X. Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des 2008; 14: 2943-2973.
6. Temming K, Schiffelers RM, Molema G, Kok RJ. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumor vasculature. Drug Resist Update 2005; 8(6): 381-402.
7. Conconi MT, Ghezzo F, Dettin M, Urbani L, Grandi C, Guidolin D, Nico B, Di Bello C, Ribatti D, Parnigotto PP. Effects on in vitro and in vivo angiogenesis induced by small peptides carrying adhesion sequences. J Pept Sci 2010; 16(7): 349-357.
8. Cai W, Rao J, Gambhir SS, Chen X. Howmolecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther 2006; 5: 2624-2633.
9. Bellis SL. Advantages of RGD peptides for directing cell association with biomaterials. Biomaterials 2011; 32: 4205-4210.
10. 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 2004; 31: 11-19.
11. 4 linker for thrombosis imaging: comparison with DMP 444. Bioconjug Chem 2011; 22(8): 1715-1722.
12. 3 integrin expression and facile radiosynthesis. J Nucl Med 2011; 52(8): 1276-1284.
13. 4 linkers. Eur J Nucl Med Mol Imaging 2009; 36(8): 1296.
14. 3 receptor-expressed tumor - MR molecular imaging of angiogenesis. Eur J Radiol 2010; 73: 420-427.
15. 3 PET imaging. Eur J Nucl Med Mol Imaging 2009; 36: 947-957.
16. 4 linkers. Bioconjug Chem 2009; 20: 750-759.
17. 99mTclabeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. J Med Chem 2008; 51: 7980-7990.
18. 3 expression. Mol Imaging 2011; 10: 386-397.
19. Mather S. Molecular imaging with bioconjugates in mouse models of cancer. Bioconjug Chem 2009; 20(4): 631-643.
20. Te Velde EA, Veerman TH, Subramaniam V, Ruers TH. The use of fluorescent dyes and probes in surgical oncology. Eur J Surg Oncol 2010; 36(1): 6-15.
21. Escobedo JO, Rusin O, Lim S, Strongin RM. NIR dyes for bioimaging applications. Curr Opin Chem Biol 2010; 14(1): 64-70.
22. Lewis JS, Achilefu S, Garbow JR, Laforest R, Welch MJ. Small animal imaging: current technology and perspectives for oncological imaging. Eur J Cancer 2002; 38(16): 2173-2188.
23. Rao JH, Dragulesu-Andrasi A, Yao HQ. Fluorescence imaging in vivo: recent advances. Curr Opin Biotechnol 2007; 18(1): 17-25.
24. Jobsis FF. Noninvasive, infrared monitoring of cerebral and myocardial oxygen sufficiency and circulatory parameters. Science 1977; 198(4323): 1264-1267.
25. Zhang C, Liu T, Su YP, Luo SL, Zhu Y, Tan X, Fan S, Zhang LL, Zhou Y, Cheng TM, Shi CM. A near-infrared fluorescent heptamethine indocyanine dye with preferential tumor accumulation for in vivo imaging. Biomaterials 2010; 31(25): 6612-6617.
26. Zhang J, Chen HY, Xu L, Gu YQ. The targeted behavior of thermally responsive nanohydrogel evaluated by NIR system in mouse model. J Control Release 2008; 131: 34-40.
27. Shan LL, Cui SS, Du CL, Wan SN, Qian ZY, Achilefu S, Gu YQ. A paclitaxel-conjugated adenovirus vector for targeted drug delivery for tumor therapy. Biomaterials 2011; 33(1): 146-162.
28. 3 expression in living mice. Bioconjug Chem 2005; 16: 1433-1441.
29. Ye YP, Bloch S, Xu BG, Achilefu S. Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem 2006; 49(7): 2268-2275.
30. Bloch S, Xu BG, Ye YP, Liang KX, Nikiforovich GV, Achilefu S. Targeting beta-3 integrin using a linear hexapeptide labeled with a near-infrared fluorescent molecular probe. Mol Pharm 2006; 3(5): 539-549.
31. 3 expression using fluorescence-mediated tomography. Eur J Nucl Med Mol Imaging 2007; 34: 734-754.
32. 3. Int J Pharm 2009; 368: 89-97.
33. Shan LL, Xue JP, Guo J, Qian ZY, Achilefu S, Gu YQ. Improved targeting of ligand-modified adenovirus as a new near infrared fluorescence tumor imaging probe. Bioconjug Chem 2011; 22(4): 567-581.
34. Ye YP, Bloch S, Xu BG, Achilefu S. Novel near-infrared fluorescent integrin-targeted DFO analogue. Bioconjug Chem 2008; 19(1): 225-234.
35. Licha K, Riefke B, Ntziachristos V, et al. Hydrophilic cyanine dyes as contrast agents for near-infrared tumor imaging: synthesis, photophysical properties and spectroscopic in vivo characterization. Photochem Photobiol 2000; 72: 392-398.
36. Maheshwari G, Brown G, Lauffenburger DA, Wells A, Griffith LG. Cell adhesion and motility depend on nanoscale RGD clustering. J Cell Sci 2000; 113: 1677-1686.